In this episode of the Oncology Brothers podcast, we dived into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treatment of renal cell carcinoma (RCC). Joined by the esteemed Dr. Monty Pal from the City of Hope, we explored the various agents available, including frontline options like cabozantinib, lenvatinib, and axitinib, as well as second-line treatments such as tivozanib and belzutifan.
We discussed the importance of starting doses and the challenges of dose titration, emphasized that side effects like hypertension, diarrhea, and hand-foot syndrome are often dose-dependent. Dr. Pal shared valuable clinical pearls on managing these common toxicities, highlighting the need for open communication with patients about their experiences and the potential need for dose adjustments.
We also touched on the overlapping side effects of TKIs and immunotherapy, particularly in cases of diarrhea. We acknowledged the historical context of older TKIs like sunitinib and pazopanib, while also recognizing the evolving landscape of treatment options.
As we wrapped up, we reiterated the significance of maintaining quality of life for our patients, especially in palliative settings.
